Disclosure
This article contains affiliate links. Quad is sold by MEDVi, BraveRX by Brave Rx, Rugiet Ready by Rugiet Health, and MyDrHank by Dr Hank — all of which run affiliate programmes we participate in, and we may earn a commission if you sign up through our links. We do not accept payment for favourable coverage, and you will see below that a commission relationship has not softened what we have written. Read our full affiliate disclosure.
This page is informational only and is not medical advice. Erectile dysfunction can be an early sign of cardiovascular disease. Speak to a licensed clinician rather than self-diagnosing from a questionnaire.
The short version
Obesity causes erectile dysfunction through a well-described mechanism, and losing weight improves it. GLP-1 medications appear to help indirectly by treating that metabolic cause, though the trial evidence specific to sexual function is thinner than the marketing suggests.
Separately: the compounded “stacked” ED products advertised alongside GLP-1 programmes combine multiple drugs in one dose. We have now reviewed three from different companies, and all three contain the same pairing — two PDE5 inhibitors whose combination is rated contraindicated by major interaction databases — with two also adding apomorphine. That is a category pattern rather than one bad product, and it is worth understanding before you buy.
Why Weight and Erectile Function Are Connected
This is not a marketing association. Erections depend on healthy blood vessels — specifically on the endothelium releasing nitric oxide so that arteries in the penis dilate and fill. Obesity and insulin resistance attack exactly that machinery: they impair endothelial function, reduce nitric oxide availability and raise chronic inflammation, all of which degrade penile blood flow.
There is a hormonal route as well. Adipose tissue converts testosterone to oestradiol, which suppresses testosterone production — a mechanism we cover in more detail in our piece on testosterone and GLP-1 weight loss. Low testosterone affects desire more than mechanics, but the two problems commonly travel together.
The practical consequence is encouraging. Reviews of the evidence report that losing even 5–10% of body weight in men with obesity can meaningfully improve erectile function scores and raise testosterone. That is a smaller weight change than most GLP-1 patients achieve.
Take this seriously as a signal
Erectile dysfunction is frequently an early marker of cardiovascular disease. The arteries supplying the penis are narrower than the coronary arteries, so they show damage sooner. New-onset ED, particularly with metabolic risk factors, is a reason to see a doctor about your cardiovascular health — not only a reason to buy a treatment for the symptom.
What GLP-1 Medications Actually Do Here
The honest answer is: probably help, mostly indirectly, on evidence that is still thin.
- A pilot study in men with obesity and metabolic hypogonadism found tirzepatide improved both erectile function and hormonal profiles, reportedly outperforming lifestyle modification and testosterone therapy in that group. Pilot studies are hypothesis-generating, not conclusive.
- Observational studies have reported improved erectile function scores in men with diabetes who achieved significant weight loss and better glycaemic control on GLP-1 therapy.
- The large trials did not measure it. The SURMOUNT programme evaluating tirzepatide for weight management did not systematically assess sexual health outcomes. That is a real gap, and it means nobody can currently quote you a reliable figure for how much GLP-1 treatment improves erectile function.
So: a reasonable expectation is that treating obesity improves erectile function, and that GLP-1s are an effective way to treat obesity. That is different from GLP-1s being an ED treatment, and any provider marketing them as one is ahead of the evidence.
The Compounded “Stacked” ED Products
Many GLP-1 telehealth companies also sell ED treatment, and a growing number sell compounded combination products — several active drugs blended into a single sublingual troche or tablet. The pitch is convenience and potency. The pharmacology deserves more attention than the marketing gives it.
Quad by MEDVi, reviewed
Quad is sold by MEDVi and lists four active ingredients: PT-141, L-citrulline, tadalafil and sildenafil. It is a rapid-absorb sublingual dose, advertised at $114 for a first month against a $179 regular price, with a doctor consultation, free rush shipping and 24/7 medical support included, and a three-minute online intake reviewed by a US-licensed doctor within 24 hours. MEDVi also advertises that if you do not qualify, you do not pay.
| Ingredient | What it is | What to know |
|---|---|---|
| Sildenafil | PDE5 inhibitor (Viagra), short-acting | Well-established, effective, decades of data as a single agent. |
| Tadalafil | PDE5 inhibitor (Cialis), long-acting | Also well-established — but taking it with sildenafil is the problem below. |
| PT-141 | Bremelanotide, a melanocortin agonist | FDA-approved only as Vyleesi for HSDD in premenopausal women. No approval for men. Raises blood pressure transiently; nausea is common. |
| L-citrulline | Amino acid, nitric oxide precursor | Available as a dietary supplement. Modest evidence at best; the least consequential ingredient here. |
The pharmacology problem
Sildenafil and tadalafil are both PDE5 inhibitors. They lower blood pressure through the same pathway, so taking them together produces additive hypotension. Major drug interaction databases flag the combination as contraindicated or major, and clinical guidance is to use one PDE5 inhibitor at a time, optimising the dose or switching agents if it is not working.
There is no established safe lower-dose version of this combination, because the risk is pharmacodynamic rather than purely dose-dependent. Compounding both into a single troche does not change that. Tadalafil also lasts far longer than sildenafil, so the overlap persists well beyond the shorter drug's window.
Add PT-141, which transiently raises blood pressure, and you have a product moving blood pressure in both directions at once. If you are considering this, that is a specific question to put to a prescriber — ideally your own doctor, not only the one reviewing a three-minute form.
And the company behind it
This matters as much as the formulation. MEDVi received an FDA warning letter dated 20 February 2026 finding its compounded GLP-1 products misbranded and its website claims misleading, and the Better Business Bureau rates it F, citing 682 complaints and a failure to respond to 100 of them. We set that out in full in our MEDVi review. None of it concerns Quad specifically, but it tells you what to expect if a billing dispute or a safety question needs answering.
A convenient format and a fair headline price, sold by a company under an FDA warning letter with an F from the BBB. The formulation combines two PDE5 inhibitors whose combination clinical guidance advises against, plus a peptide with no FDA approval in men. There are simpler, better-evidenced ways to treat this.
Discuss the two-PDE5-inhibitor combination with a clinician first
BraveRX, and a Warning That Matters Specifically to GLP-1 Patients
BraveRX is a Miami telemedicine service selling a single oral dissolving tablet at $159 for a 12-count bottle, with a complimentary doctor visit, daily medical support and free shipping included, available in every state except North Dakota. Its intake questionnaire is more detailed than the perfunctory ones several competitors use, which counts in its favour, and it carries strong public review numbers.
Its formulation, as listed on its own page, is tadalafil 15mg, sildenafil 40mg and apomorphine 3mg. (Some third-party write-ups list icariin in place of sildenafil, so confirm the exact formulation you are prescribed.) Two things follow from that ingredient list, and the second is the reason this section exists.
First, the same problem as Quad above: tadalafil and sildenafil are both PDE5 inhibitors, and 40mg of sildenafil alongside 15mg of tadalafil is not a trivial pairing. Interaction databases flag the combination as contraindicated or major because the blood-pressure lowering is additive, and clinical guidance is to use one PDE5 inhibitor at a time.
Second, apomorphine. It is a dopamine agonist that was sold for ED as Uprima from 2001 and discontinued in 2006; it is not a currently approved ED treatment in the US. In trials of sublingual apomorphine at 3mg, the proportion of attempts producing an erection firm enough for intercourse was 49.4% against a 24.3% baseline. Its documented adverse effects include headache, dizziness, yawning, chest pain, hypotension and vasovagal symptoms — and, most commonly of all, nausea and vomiting.
If you take ondansetron for GLP-1 nausea, read this
Apomorphine is contraindicated with 5-HT3 antagonists. The reason is specific: profound hypotension and loss of consciousness have been reported when apomorphine was given alongside ondansetron. The contraindication covers the whole class — ondansetron, granisetron, dolasetron, palonosetron and alosetron.
Ondansetron, sold as Zofran, is one of the most commonly prescribed medications for exactly the nausea GLP-1 treatment causes. So there is a realistic scenario here that almost nobody is joining up: a patient on a GLP-1, prescribed ondansetron for nausea during titration, buys a three-in-one ED tablet online without either prescriber knowing about the other, and takes a contraindicated combination.
If you take or have been prescribed ondansetron, do not take an apomorphine-containing product without speaking to a clinician who knows about both. And note the second irony: apomorphine is a potent emetic in its own right, so it is a poor choice for anyone already managing GLP-1 nausea.
A well-run service with a thorough intake and good reviews, selling a formulation we would not recommend to this audience. It stacks two PDE5 inhibitors that guidance says to use one at a time, adds a discontinued ED drug that is a potent emetic and lowers blood pressure further, and creates a contraindication with the anti-nausea medication many GLP-1 patients are already taking. Prescription treatments are also non-refundable once shipped.
Contains apomorphine · Do not combine with ondansetron · Speak to a clinician first
Rugiet Ready — the Same Stack, Best Executed
Rugiet Health is the most established seller of this formulation, and its product is the same one. Rugiet Ready is a compounded sublingual troche combining sildenafil, tadalafil and apomorphine — the identical three-drug stack as BraveRX, and the same two-PDE5-inhibitor pairing as Quad.
Where Rugiet differs is execution and candour. It states its ingredients and their roles plainly — apomorphine for dopamine-mediated arousal, sildenafil and tadalafil for blood flow — rather than burying them. It has spent years on a bitterness-masking technology for the troche, ships within 48 hours, and carries a substantial public record: around 4 stars across more than 1,100 Trustpilot reviews as of early 2026, with users reporting onset in 10 to 20 minutes and effects lasting 24 to 36 hours. Pricing runs $149 to $269 a month, roughly $12 to $22 per dose on a twelve-dose plan, with promotional bundles advertised down to about $7.29 per dose. It also runs a TRT programme from $139/month with lab monitoring included after a $69 blood test.
Three companies, one formulation
This is now the third product on this page built on the same pairing, from three unrelated companies. That tells you the combination is a commercial formula rather than a clinical one — it is differentiated, it is patentable-feeling, and it cannot be bought as a generic. None of that changes the pharmacology.
Sildenafil and tadalafil lower blood pressure through the same pathway, and interaction databases flag taking them together as contraindicated or major. The 24-to-36-hour duration users report is consistent with tadalafil's long half-life — which also means the window in which that additive effect applies is long. Add apomorphine, which lowers blood pressure further and is contraindicated with ondansetron, and the case for a single generic PDE5 inhibitor gets stronger rather than weaker.
Genuinely the strongest operator selling this stack — ingredients named openly, a real review base, fast shipping, and a TRT programme that includes lab monitoring. It scores higher than its two competitors here for candour and execution, and still low because the formulation combines two PDE5 inhibitors that guidance says to use one at a time, plus apomorphine.
Contains apomorphine · Two PDE5 inhibitors · Discuss with a clinician first
MyDrHank — What the Conservative Route Looks Like
Having spent two sections explaining why we would not recommend stacked multi-drug ED products, it is only fair to show what the alternative looks like in practice. MyDrHank is the closest thing in this space to the approach clinical guidance actually supports.
It sells standard FDA-approved generic sildenafil and tadalafil — one PDE5 inhibitor at a time, in conventional dosages, with tadalafil available both as-needed and daily. No apomorphine, no PT-141, no two-inhibitor combination. It is a pharmacy-owned telehealth platform founded by a licensed pharmacist, operating since 2018 from Nashville, and holds LegitScript certification. Consultations are free, and advertised pricing runs around $1.67 to $2.08 per dose.
That last figure is worth pausing on. Sildenafil and tadalafil came off patent years ago and are genuinely cheap as generics. A large part of what the stacked compounded products are selling is novelty rather than efficacy — and novelty here means combinations that clinical guidance advises against, at multiples of the price of the medication that works.
The trade-offs, stated plainly
MyDrHank does not accept insurance, and does not take FSA or HSA cards — it is a credit-card, out-of-pocket service. Its public review record is mixed rather than uniformly positive. And a generic PDE5 inhibitor is not a magic answer: if one does not work for you at an optimised dose, the guidance is to switch to the other, not to take both.
The nitrate rule applies here exactly as it does to any ED medication. If you take nitrates in any form, including recreational poppers, PDE5 inhibitors are not safe for you.
The boring option, and the one clinical guidance actually supports: a single FDA-approved generic PDE5 inhibitor at a sensible dose and a low price, from a pharmacist-founded, LegitScript-certified platform operating since 2018. No insurance or HSA/FSA acceptance, and mixed public reviews — but no pharmacological problems to explain either.
FDA-approved generics · One PDE5 inhibitor at a time · Never with nitrates
A More Conservative Route
- Start with one PDE5 inhibitor, properly dosed. Sildenafil and tadalafil are cheap as generics, extremely well studied, and effective for most men. Guidance is to optimise one before adding anything.
- Rule out nitrates first. PDE5 inhibitors with nitrates — including angina medication and recreational poppers — can cause a catastrophic blood pressure drop. Non-negotiable.
- Treat the metabolic cause in parallel. If obesity is driving it, weight loss addresses the mechanism rather than the symptom. Our provider reviews cover the GLP-1 options.
- Get your cardiovascular risk assessed. ED is an early warning sign. Treating it without checking what it is signalling is a missed opportunity.
- Ask about testosterone only after weight loss. Functional hypogonadism from obesity often resolves as weight comes off — see our testosterone guide.
If the Problem Is Timing, Not Erection
Everything above this line is about erectile dysfunction — difficulty getting or keeping an erection. Premature ejaculation is a different condition, and the two get conflated constantly, which matters here for a practical reason: none of the products discussed on this page treat it. A tadalafil and sildenafil stack does nothing for timing. If you buy one for a timing problem you will have spent money on the wrong thing.
The distinction is worth drawing on a GLP-1 page specifically, because weight loss improves erectile function through the vascular and hormonal mechanisms described at the top of this article — and it does not do anything comparable for ejaculatory control. Losing 20% of your body weight may well fix one problem while leaving the other exactly where it was.
Which problem do you actually have?
Erectile dysfunction — difficulty achieving or maintaining an erection firm enough for sex. This is what PDE5 inhibitors treat, and what weight loss improves.
Premature ejaculation — ejaculation sooner than you or your partner would like, consistently and distressingly. Different mechanism, different treatments: topical anaesthetics, certain SSRIs prescribed off-label, and behavioural approaches.
You can have both. One randomised trial specifically studied on-demand tadalafil alone versus tadalafil combined with a lidocaine spray in men with both conditions, which tells you how often they travel together.
The evidence for topical anaesthetics is better than for anything else on this page
This is the genuinely interesting part. The compounded ED stacks reviewed above rest on the evidence for their individual components rather than for the combination as sold. Topical lidocaine for premature ejaculation has been tested directly and repeatedly: a systematic review and meta-analysis pooling eleven randomised controlled trials across 2,008 participants found topical lidocaine significantly more effective than placebo at increasing intravaginal ejaculatory latency time. A separate randomised trial comparing it against oral dapoxetine found both increased IELT, with the topical lidocaine performing better.
Promescent is the best-known consumer product in that category. It is an over-the-counter topical anaesthetic containing lidocaine 10mg per spray, with the drug facts use stated as “Helps in temporarily slowing the onset of ejaculation” — an OTC monograph drug product rather than a supplement, which is a meaningful regulatory difference from most things marketed for sexual performance. Directions are three or more sprays and not more than ten, applied to the head and shaft ten minutes before intercourse, washed off afterwards. It is $22.95 for a 20-spray bottle and $59.95 for 60 sprays, with a 30-day money-back guarantee.
Its distinguishing marketing claim is an “Anti-Transfer” formulation intended to absorb into the skin so it does not numb a partner — the washing-off instruction exists for the same reason, and it is worth following regardless of the claim. Promescent also cites a 2016 study in the International Journal of Impotence Research reporting a 50% increase in both partners reaching orgasm together. Read that for what it is: a study of the quality of sexual experience, cited by the company that sells the product, rather than an independent IELT trial. The stronger case for the product is the category evidence above, not that citation.
Two practical cautions
Lidocaine can cause local irritation or allergic reaction, and over-application reduces sensation to a degree many people find counterproductive. Start at the low end of the dose range rather than the top of it.
And if premature ejaculation is new rather than lifelong, that is worth a conversation with a clinician rather than a purchase. New-onset ejaculatory change can accompany anxiety, relationship stress, thyroid disease and some medications — including SSRIs, which cut both ways here. A spray manages a symptom; it does not tell you why it started.
OTC lidocaine spray · Treats timing, not erections · 30-day money-back guarantee
Frequently Asked Questions
Will a GLP-1 help with premature ejaculation?
There is no evidence that it will, and it is a different problem from the one weight loss addresses. Losing weight improves erectile function through vascular and hormonal mechanisms with a solid evidence base behind them. Ejaculatory control is not governed by the same pathway, and nothing in the GLP-1 literature speaks to it. If timing is your concern, the treatments with evidence are topical anaesthetics, certain SSRIs prescribed off-label, and behavioural approaches — not a PDE5 inhibitor and not a weight-loss drug.
Do lidocaine delay sprays actually work?
For premature ejaculation, the evidence is better than for most things sold in this space. A systematic review and meta-analysis pooling eleven randomised controlled trials across 2,008 participants found topical lidocaine significantly more effective than placebo at increasing intravaginal ejaculatory latency time, and a randomised trial against oral dapoxetine found the topical route performed better. Products such as Promescent are over-the-counter topical anaesthetics — Promescent contains lidocaine 10mg per spray — rather than supplements, which is a real regulatory difference. The practical cautions are local irritation, transfer to a partner (wash it off afterwards), and over-application dulling sensation more than you want.
Does losing weight improve erectile dysfunction?
Frequently, yes, and the mechanism is well understood. Obesity and insulin resistance drive endothelial dysfunction, reduce nitric oxide availability and raise chronic inflammation — all of which impair the blood flow erections depend on. Reviews of the evidence report that losing even 5–10% of body weight in men with obesity can meaningfully improve erectile function scores and raise testosterone. Erectile dysfunction is also an early marker of cardiovascular disease, so it is worth raising with a doctor rather than only treating symptomatically.
Do GLP-1 medications help erectile dysfunction?
The evidence is encouraging but genuinely limited, and you should treat any confident claim with suspicion. A pilot study in men with obesity and metabolic hypogonadism found tirzepatide improved both erectile function and hormonal profiles. Observational studies have reported improvements among men with diabetes who lost significant weight on GLP-1 therapy. But the large SURMOUNT trials of tirzepatide did not systematically assess sexual health outcomes, which leaves a real gap. The most defensible summary is that GLP-1s appear to help erectile function indirectly, by treating the metabolic problems that cause it.
Is it safe to combine sildenafil and tadalafil?
Clinical guidance says no. Both are PDE5 inhibitors working through the same pathway, so combining them produces additive blood-pressure lowering that can cause dangerous hypotension, and major drug interaction databases rate the combination as contraindicated or major. There is no established safe lower-dose version of this, because the risk is pharmacodynamic rather than purely dose-dependent. Guidelines recommend optimising a single PDE5 inhibitor and, if that fails, switching to a different one — not taking two at once. Compounding both into one product does not change the pharmacology.
What is PT-141 and is it approved for men?
PT-141 (bremelanotide) is a melanocortin agonist approved by the FDA in June 2019 as Vyleesi, for hypoactive sexual desire disorder in premenopausal women. It has no FDA approval for any condition in men, including erectile dysfunction or low libido, and approval for men has not been pursued — though Phase II data in men exists. It also raises blood pressure transiently, which was the basis of a 2007 FDA clinical hold on an intranasal formulation, and a cardiovascular warning remains on the approved label. Nausea is its most common side effect.
Can I take an ED medication with nitrates?
No. This is the one absolute rule in this area. PDE5 inhibitors taken with nitrates — including nitroglycerin for angina, and including recreational "poppers" (amyl nitrite) — can cause a catastrophic drop in blood pressure. This is a genuine medical emergency risk, not a precaution. If you take nitrates in any form, tell the prescriber before you buy anything, and do not rely on an online questionnaire to catch it.
Should I treat erectile dysfunction or the weight first?
It is not either/or, and this is a conversation for a clinician rather than a checkout page. Symptomatic treatment works quickly and there is nothing wrong with wanting it. But erectile dysfunction driven by metabolic disease is a signal about your cardiovascular health, and treating only the symptom leaves the cause running. If you are starting a GLP-1 anyway, you are already treating the underlying problem.
Where to Go Next
- Testosterone and GLP-1 weight loss — the hormonal half of this picture
- MEDVi review — the FDA warning letter and BBB record in full
- GLP-1 provider reviews — if treating the underlying cause is the priority
Medical Disclaimer
We're not doctors, and this article is for education only — it isn't medical advice. GLP-1 medications are prescription-only and require evaluation by a licensed healthcare provider. Individual results vary widely, and only a clinician who knows your history can determine what is safe and appropriate for you. See our full medical disclaimer.
Keep Comparing
Every provider we've researched, with published pricing, medication type, and what's actually included.
Affiliate Disclosure: This article may contain affiliate links. If you sign up through one, we may earn a commission at no additional cost to you. We do not accept payment for favorable coverage. Read our full affiliate disclosure policy.